In previous experimental animal studies it has been demonstrated that antibody depletion is not followed by increased antibody synthesis. To assess whether these results are conferrable to antibody-depleted humans, we measured free light chains (flcs) as markers of current antibody synthesis in 8 patients treated with immunoadsorption (IA) therapy. Specific and bulk immunoglobulin levels were obtained simultaneously. The mean serum flc concentration increased to the preapheresis value within 1 day and remained unchanged thereafter. Total immunoglobulin G (IgG) and specific antibody concentrations increased to pretreatment values in 88% and 43% of the patients, respectively, and remained below the original values in the others. In conclusion, the lack of increased flc synthesis after IA confirms the absence of a feedback mechanism regulating antibody synthesis. The restoration of serum IgG levels after IA, therefore, does not result from increased antibody synthesis but is probably related to changes of catabolism and immunoglobulin backflow.

The regulation of serum antibody levels has been a subject of debate for several decades. A large number of studies have provided evidence for enhanced antibody synthesis after immunoglobulin depletion and thus for the existence of an immunoregulatory feedback mechanism.1-7 In contrast, Charlton and colleagues8-10 demonstrated with a series of animal experiments that the rapid increase of antibody serum levels after plasmapheresis could be explained by immunoglobulin backflow from extravascular space and decreased catabolism alone. More than 10 years later the lack of an increased antibody synthesis in a low immunoglobulin state was confirmed in the excellent studies by Junghans and Anderson11 and by Junghans.12 Knock-out mice with disrupted immunoglobulin G (IgG) protection receptors, which effect increased catabolism of IgG and subsequently low IgG serum levels, had a similar biosynthesis rate as normal control subjects.

The complex metabolism of IgG has so far prevented exact measurement of immunoglobulin synthesis in humans with low antibody levels. However, a prerequisite for immunoglobulin assembly is the synthesis of free light chains (flcs) that are produced in excess during antibody production and secreted as free κ or λ monomers into the vascular space.13,14 Because flcs have a half-live of only 2 to 4 hours,15 they reflect current immunoglobulin production and can be used for estimating the activity of diseases accompanied by autoantibody synthesis.16 17 We hypothesized that increased antibody synthesis after immunoglobulin depletion would be accompanied by increased flc serum levels and measured free κ and λ light chain concentrations in 8 patients undergoing immunoadsorption (IA) therapy.

The study protocol was approved by the local ethics committee, and the patients' informed consent was obtained. Eight patients with various autoimmune diseases and normal kidney function treated with IA therapy were recruited (Table 1). Concomitant immunosuppressive therapy was prednisolone (n = 4), mycophenolate mofetil (n = 3), and cyclosporine A (n = 1); 3 patients received no additional therapy. We recruited additionally 3 patients with familial hypercholesterolemia, who were treated with regular low-density lipoprotein (LDL)–cholesterol apheresis, as control subjects. The IA and LDL apheresis therapy procedure used at our institution was described previously.18,19 In brief, peripheral venous blood was drawn and the plasma separated by centrifugation. Thereafter the plasma was treated with either Ig-Therasorb columns (Therasorb, Munich, Germany), coated with sheep antihuman immunoglobulin antibodies, or LDL-Therasorb columns (Therasorb), coated with anti-LDL antibodies. Blood samples were analyzed immediately before and after plasmapheresis and at days 1, 3, and 5 after treatment. Measurement of flc was performed by a latex-enhanced immunoassay20 with a lower detection range for free κ and λ light chains of 3.4 mg/L. The blood levels of serum immunoglobulins (IgG, IgA, IgM) and of specific autoantibodies (thyroglobulin, acetylcholine receptor, double-stranded DNA (dsDNA), and antinuclear antibody/antinuclear factor) were determined with the use of standard methods. To exclude only B-cell activation by IA therapy or activation of the underlying disease, which would have increased immunoglobulin synthesis and interfered with the flc synthesis rate, in vivo B-cell activity was measured by 4-color flow cytometry before and during the post-IA period by using 3 different antibodies (CD38, CD43, and CD22; all antibodies by Immunotech, Marseille, France). Activation of B cells was defined as an increase of CD38 and CD43 expression and reduction of CD22 expression.

Table 1.

Patient characteristics at study entrance

Patient no.Autoimmune diseaseSexAge, yTime since IA, moImmunosuppressive therapy, mg/day
PREMMCyA
EO 59 — — — 
MG 30 43 10 2000 — 
SLE 28 20 500 250 
MG 27 57 — 2000 — 
EO 49 14 — — — 
SLE 37 19 7.5 — — 
EO 54 — — — 
GB 74 15 — — 
Patient no.Autoimmune diseaseSexAge, yTime since IA, moImmunosuppressive therapy, mg/day
PREMMCyA
EO 59 — — — 
MG 30 43 10 2000 — 
SLE 28 20 500 250 
MG 27 57 — 2000 — 
EO 49 14 — — — 
SLE 37 19 7.5 — — 
EO 54 — — — 
GB 74 15 — — 

IA indicates immunoadsorption; PRE, prednisolone; MM, mycophenolate mofetil; CyA, cyclosporine A; EO, endocrine orbitopathy; MG, myasthenia gravis; SLE, systemic lupus erythematosus; and GB, Guillain-Barré syndrome.

The results are expressed as median and range. Statistical analysis was carried out by the Student t test for paired or unpaired data or Wilcoxon signed rank test. A P value < .05 was considered statistically significant.

Free κ light chain levels decreased in 7 of 8 patients during IA and remained unchanged in one patient (Table2). The levels increased to pretreatment values in most patients within 1 day (median difference to pretreatment values, −2% [range, −41% to 62%] with one patient below detectable limit) and remained stable thereafter (Table 2). Only one patient had a κ light chain pretreatment level above normal range (patient 8), which decreased by IA but remained slightly above normal range during the observation period (normal, 8.4 ng/mL; range, 3.6-15.9 ng/mL). Flc of the λ type decreased similarly during IA in all patients (Table 2). Almost all patients reached pretreatment values within 24 hours (median difference, −1%; range, −14% to 15%). The levels remained within normal range during the further course (normal, 14.5 ng/mL [range, 8.1-33 ng/mL]). The median κ/λ ratio in patients with measurable free κ light chain levels was 0.49 (range, 0.33-1.30) before treatment and remained within normal range during the posttreatment period (mean, 0.54 [range, 45-0.63]; normal, 0.6 [range, 0.36-1.0]). Free κ and λ light chain levels before and after therapy in the 3 control patients with LDL apheresis remained unchanged throughout the study (mean κ, 15 ng/mL [range, 13-17 ng/mL] and mean λ, 18 ng/mL [range, 18-19 ng/mL]). IgG serum levels decreased by approximately 90% during IA and increased to approximately 70% of pretreatment levels within 5 days (Table3). There was a tendency toward a slower increase of serum levels in patients receiving no adjunctive immunosuppressants (n = 4) than in patients with additional mycophenolate mofetil, cyclosporine A, or prednisolone (> 10 mg/day) therapy (median, 69%; range, 63%-85% versus 81%; range, 63%-94%;P = NS). IgM and IgA decreased by 61% (range, 47%-81%) and 68% (range, 47%-81%), respectively, and increased within 5 days to 75% (range, 52%-111%) and 81% (range, 79%-98%), respectively, of pretreatment levels. Immunoglobulin levels remained unchanged in the control patients treated with LDL apheresis. Specific antibody levels decreased substantially during IA in all patients with identifiable autoimmune disease and increased to pretreatment values in 4 of 7 patients within 5 days (Table 3).

Table 2.

Individual free light chain serum levels before and immediately after immunoadsorption and at days 1, 3, and 5 after treatment

Patient no.Free κ light chain, mg/LFree λ light chain, mg/L
Before IAAfter IAD1D3D5Before IAAfter IAD1D3D5
4.1 < 3.4 < 3.4 < 3.4 < 3.4 8.7 5.4 10 9.8 10 
4.0 4.3 5.2 < 3.4 6.6 15 7.2 14 13 15 
11 4.0 7.4 8.5 9.1 16 7.3 14 15 17 
8.1 7.9 8.4 16 16 17 12 19 22 21 
4.0 < 3.4 5.5 < 3.4 < 3.4 12 5.8 10 12 12 
6.6 < 3.4 6.5 4.5 6.5 20 9.2 21 19 18 
< 3.4 4.7 15 9.7 14 16 18 
35 24 32 28 29 27 22 30 23 28 
Patient no.Free κ light chain, mg/LFree λ light chain, mg/L
Before IAAfter IAD1D3D5Before IAAfter IAD1D3D5
4.1 < 3.4 < 3.4 < 3.4 < 3.4 8.7 5.4 10 9.8 10 
4.0 4.3 5.2 < 3.4 6.6 15 7.2 14 13 15 
11 4.0 7.4 8.5 9.1 16 7.3 14 15 17 
8.1 7.9 8.4 16 16 17 12 19 22 21 
4.0 < 3.4 5.5 < 3.4 < 3.4 12 5.8 10 12 12 
6.6 < 3.4 6.5 4.5 6.5 20 9.2 21 19 18 
< 3.4 4.7 15 9.7 14 16 18 
35 24 32 28 29 27 22 30 23 28 

IA indicates immunoadsorption; D1, day 1; D3, day 3; and D5, day 5.

Table 3.

Total immunoglobulin G and specific antibody levels before and immediately after immunoadsorption and at days 1, 3, and 5 after treatment

Patient no.Total IgG, mg/LD1D3D5Specific antibodyBefore IAAfter IAD1D3D5
Before IAAfter IA
226 < 30 63 110 149 Thyroglobulin Ab, U/L 9   < 3   8   10   
492 33 443 433 459 Acetylcholine-receptor Ab, nmol/L 76   4.7 49 71   92   
450 35 146 216 282 dsDNA, IU/mL 9.4 < 1   < 1 5.1 6.2 
681 112 274 401 481 Acetylcholine-receptor Ab, nmol/L 48   9   13 25   24   
431 < 30 167 279 296 Thyroglobulin Ab, U/L 17   < 3   14   11   
521 43 352 445 490 ANA, highest positive dilution 1:640 1:80 1:320 1:320 1:320 
384 42 158 263 326 Thyroglobulin Ab, U/L 7   < 3   4   6   
1170 150 433 430 623 Unknown — — — — — 
Patient no.Total IgG, mg/LD1D3D5Specific antibodyBefore IAAfter IAD1D3D5
Before IAAfter IA
226 < 30 63 110 149 Thyroglobulin Ab, U/L 9   < 3   8   10   
492 33 443 433 459 Acetylcholine-receptor Ab, nmol/L 76   4.7 49 71   92   
450 35 146 216 282 dsDNA, IU/mL 9.4 < 1   < 1 5.1 6.2 
681 112 274 401 481 Acetylcholine-receptor Ab, nmol/L 48   9   13 25   24   
431 < 30 167 279 296 Thyroglobulin Ab, U/L 17   < 3   14   11   
521 43 352 445 490 ANA, highest positive dilution 1:640 1:80 1:320 1:320 1:320 
384 42 158 263 326 Thyroglobulin Ab, U/L 7   < 3   4   6   
1170 150 433 430 623 Unknown — — — — — 

IgG indicates immunoglobulin G; IA, immunoadsorption; D1, day 1; D3, day 3; D5, day 5; Ab, antibody; and ANA, antinuclear antibody.

The 3 different activity markers (CD22, CD38, and CD43) identified on CD19+ lymphocytes showed a normal distribution in 6 of 8 investigated patients and were not influenced by IA (data not shown). Two patients had activated B cells prior to initiation of therapy. Patient 6 had markedly increased CD38+ B cells (98%), which decreased after IA (78%). In patient 8, CD38+ (78%) and CD43+ (74%) were increased and CD22+(42%) decreased and normalized after IA therapy (CD38+, 19%; CD43+, 21%; and CD22+, 94%). The 3 patients treated with LDL apheresis had a normal distribution of CD38+, CD43+, and CD22+ B cells throughout the study.

Thus, we were able to demonstrate that immunoglobulin depletion with IA does not influence antibody synthesis which agrees with previous animal experiments describing the lack of an immunoglobulin feedback mechanism.8-11 The close correlation between flc concentration and immunoglobulin synthesis has been demonstrated in several conditions associated with B-cell activation, such as multiple sclerosis16 and systemic lupus erythematodes.17 Because B-cell activation and antibody synthesis precedes tissue injury by several weeks, flcs might even be used as reliable predictors for subsequent clinical relapse of disease.21 Thus, by demonstrating that flc serum levels remained unchanged after immunoglobulin depletion, we were able to prove that a reduction of antibody serum levels is not followed by an increased biosynthesis. Moreover, because immunoadsorption therapy not only reduced IgG but also IgM and IgA serum levels by 60% to 70% because of the use of a nonspecific adsorption column, an intrinsic feedback mechanism of other immunoglobulin classes might be excluded as well.

The lack of an accelerated antibody synthesis after immunoglobulin depletion makes the widely accepted strategy of administering cytotoxic drugs during plasmapheresis, to prevent an accelerated antibody production,22 obsolete. The insufficiency of prophylactic immunosuppressive therapy on antibody rebound was demonstrated in our patients by the similar immunoglobulin increase in those treated with additional immunosuppressants, when compared with patients without concomitant cytostatic drugs. Antibody levels as well as flc levels did not differ between the groups and increased to pretreatment values equally fast. Similar to others9 12 we cannot, therefore, recommend the administration of immunosuppressants for the prevention of an increased antibody synthesis after plasmapheresis. However, patients with a chronic autoimmune disease, treated with plasmapheresis either as a result of acute exacerbation or as a long-term therapeutic strategy, will, nevertheless, profit in most cases from the long-term effects of immunosuppressants.

The absence of an increase of B-cell activity after IA contradicts a previous study7 but, nevertheless, excludes the possibility that IA therapy itself might promote antibody synthesis by release of antigenic peptides. On the contrary, as indicated in the patient with active Guillain-Barré syndrome, characterized serologically by highly activated B cells and increased κ light chains, removal of autoantibodies and immune complexes might lead to a normalization of both B-cell activity markers and flc levels. It is, therefore, tempting to speculate that antibody removal might not only be without influence on immunoglobulin synthesis but also by interrupting the inflammatory process even decrease B-cell activity and antibody production.

In conclusion, our study shows that antibody synthesis in humans is not regulated by a biofeedback mechanism. These findings are in line with similar results found in rabbits and knockout mice.8-11Administration of cytotoxic drugs for inhibition of a supposed antibody rebound should, therefore, be avoided, because it has no influence on postapheresis synthesis rate but implies an additional risk for the patient.

The flc Kits were provided by “The Binding Site,” Birmingham, England.

We thank Professor I.C.M. Maclennan, Birmingham, United Kingdom, and Professor G. Zlabinger, Vienna, Austria, for valuable discussion, and Mrs. Konstantin and Mrs. Czarnecki for excellent technical assistance.

Prepublished online as Blood First Edition Paper, April 17, 2002; DOI 10.1182/blood- 2002-01-0128.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Graf
MW
Uhr
JW
Regulation of antibody formation by serum antibody. I. Removal of specific antibody by means of immunoadsorption.
J Exp Med.
130
1969
1175
1186
2
Terman
DS
Garcia-Rinaldi
R
Dannemann
B
et al
Specific suppression of antibody rebound after extracorporeal immunoadsorption, I: comparison of single versus combination chemotherapeutic agents.
Clin Exp Immunol.
34
1978
32
41
3
Euler
HH
Krey
U
Schröder
O
Löffler
H
Membrane plasmapheresis technique in rats. Confirmation of antibody rebound.
J Immunol Methods.
84
1985
313
319
4
Reding
R
White
DJG
Wright
LJ
et al
Qualitative analysis of antibody rebound after plasma exchange in the rat.
Transplant Proc.
21
1989
777
778
5
Follette
DB
Kerr
D
Nasca
TJ
Euler
HH
Pinevich
AJ
A method for chronic membrane plasmapheresis in the rat.
J Appl Physiol.
75
1993
2820
2824
6
Dau
PC
Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease.
J Neuroimmunol.
30
1990
15
21
7
Dau
PC
Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis.
J Neuroimmunol.
62
1995
197
200
8
Charlton
B
Schindhelm
K
Smeby
LC
Farrell
PC
Analysis of immunoglobulin G kinetics in the non-steady state.
J Lab Clin Med.
105
1985
312
320
9
Charlton
B
Schindhelm
K
The effect of extracorporeal antibody removal on antibody synthesis and catabolism in immunized rabbits.
Clin Exp Immunol.
60
1985
457
464
10
Charlton
B
Schindhelm
K
Farrell
PC
Effect of extracorporeal IgG removal on IgG kinetics.
Trans Am Soc Artif Intern Organs.
29
1983
724
729
11
Junghans
RP
Anderson
CL
The protection receptor for IgG catabolism is the β2-microglobulin-containing intestinal transport receptor.
Proc Natl Acad Sci U S A.
93
1996
5512
5516
12
Junghans
RP
IgG biosynthesis: no “immunoregulatory feedback.”
Blood.
90
1997
3815
3818
13
Levinson
SS
Keren
DF
Free light chains of immunoglobulins: clinical laboratory analysis.
Clin Chem.
40
1994
1869
1878
14
Askonas
BA
Williamson
AR
Biosynthesis of immunoglobulins. Free light chain as an intermediate in the assembly of βG-molecules.
Nature.
211
1966
369
372
15
Sølling
K
Free light chains of immunoglobulins.
Scan J Clin Lab Invest.
41
1981
15
83
16
Mehta
PD
Cook
SD
Troiano
RA
Coyle
PK
Increased free light chains in the urine from patients with multiple sclerosis.
Neurology.
41
1991
540
544
17
Hopper
JE
Golbus
J
Meyer
C
Ferrer
GA
Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig.
J Clin Immunol.
20
2000
123
137
18
Haas
M
Godfrin
Y
Oberbauer
R
et al
Plasma immunoadsorption treatment in patients with primary focal and segmental glomerulosclerosis.
Nephrol Dial Transplant.
13
1998
2013
2016
19
Schmaldienst
S
Banyai
S
Stulnig
TM
et al
Prospective randomised cross-over comparison of three LDL-apheresis systems in statine pretreated patients with familial hypercholesterolaemia.
Atherosclerosis.
151
2000
493
499
20
Bradwell
AR
Carr-Smith
HD
Mead
GP
et al
Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.
Clin Chem.
47
2001
673
680
21
Hopper
JE
Sequeira
W
Martellotto
J
Papagiannes
E
Perna
L
Skosey
JL
Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin.
J Clin Immunol.
9
1989
338
350
22
Dau
PC
Immunologic rebound.
J Clin Apheresis.
10
1995
210
217

Author notes

Martin Haas, Department of Internal Medicine III, Division of Nephrology and Dialysis, University Hospital Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria; e-mail:martin.haas@akh-wien.ac.at.

Sign in via your Institution